Literature DB >> 9218872

7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells.

R T Bunch1, A Eastman.   

Abstract

A variety of agents, such as caffeine, have been shown to abrogate the DNA damage-dependent G2 checkpoint and enhance cytotoxicity. However, these agents are too toxic for clinical use. We have reported that the potent protein kinase inhibitor 7-hydroxystaurosporine (UCN-01) at nontoxic doses abrogates the G2 arrest caused by the DNA-damaging agent cisplatin. Here, using Chinese hamster ovary cells, we show that cisplatin causes predominantly an S-phase arrest; UCN-01 abrogates this S-phase arrest, causing progression of cells to G2 and, subsequently, apoptotic cell death. In searching for an explanation for this accelerate DNA synthesis, we discovered that UCN-01 caused translocation of proliferating cell nuclear antigen (PCNA) to the detergent-insoluble, DNA-bound fraction. PCNA acts as a sliding clamp for DNA polymerase delta. Sequestering of PCNA by p21waf1/cip1 is required for p53-dependent G1 arrest in damaged cells. However, the S-phase arrest occurs independently of p53 and p21waf1/cip1. Our results suggest that PCNA is also a component of this S-phase checkpoint, despite the fact that CHO cells are defective for p53, and no increase in p21waf1/cip1 was observed. The mechanism by which PCNA is sequestered in the absence of p21waf1/cip1 and the mechanism by which UCN-01 disrupts this sequestration remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218872

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  12 in total

1.  UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Authors:  A Monks; E D Harris; A Vaigro-Wolff; C D Hose; J W Connelly; E A Sausville
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

2.  HPV16-E7 expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells.

Authors:  M D Axelson; M A Davis; S P Ethier; T S Lawrence
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

3.  Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase.

Authors:  Z Sever-Chroneos; S P Angus; A F Fribourg; H Wan; I Todorov; K E Knudsen; E S Knudsen
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 4.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  New targets and challenges in the molecular therapeutics of cancer.

Authors:  Alan Eastman; Raymond P Perez
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

6.  AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation.

Authors:  Esther P Jane; Daniel R Premkumar; Ian F Pollack
Journal:  Cancer Lett       Date:  2007-11-08       Impact factor: 8.679

Review 7.  Biologic directed therapies in gynecologic oncology.

Authors:  John H Farley; Michael J Birrer
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 8.  Clinical anticancer drug development: targeting the cyclin-dependent kinases.

Authors:  C Benson; S Kaye; P Workman; M Garrett; M Walton; J de Bono
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

9.  Anti-tumor activity of Eurycoma longifolia root extracts against K-562 cell line: in vitro and in vivo study.

Authors:  Omar Saeed Ali Al-Salahi; Dan Ji; Amin Malik Shah Abdul Majid; Chan Kit-Lam; Wan Zaidah Abdullah; Abdelhamid Zaki; Shah Kamal Khan Jamal Din; Narazah Mohd Yusoff; Aman Shah Abdul Majid
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

10.  Induction of apoptosis and cell cycle blockade by helichrysetin in a549 human lung adenocarcinoma cells.

Authors:  Yen Fong Ho; Saiful Anuar Karsani; Wai Kuan Yong; Sri Nurestri Abd Malek
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-03       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.